Antimicrobial-resistant Streptococcus pneumoniae: trends and management

References

• Barnett ED, Klein JO. The problem of resistant bacteria for the management of acute otitis media. Pediatr. Clin. North Am.42(3), 509–517 (1995).
   PubMed Web of Science ®Google Scholar
• Jones ME, Draghi DC, Karlowsky JA, Sahm DF, Bradley JS. Prevalence of antimicrobial resistance in bacteria isolated from central nervous system specimens as reported by U.S. hospital laboratories from 2000 to 2002. Ann. Clin. Microbiol. Antimicrob.3(1), 3 (2004).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Defining the public health impact of drug-resistant Streptococcus pneumoniae: report of a working group. MMWR Recomm. Rep.45(RR-1 Suppl.), 1–20 (1996).
   Google Scholar
• Centers for Disease Control and Prevention. Epidemiology & Prevention of Vaccine-Preventable Diseases (9th Edition). Atkinson W, Hamborsky J, Wolfe S (Eds). Public Health Foundation, Washington, DC, USA (2006).
   Google Scholar
• Robinson KA, Baughman W, Rothrock G et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998: opportunities for prevention in the conjugate vaccine era. JAMA285(13), 1729–1735 (2001).
   PubMed Web of Science ®Google Scholar
• Tsai CJ, Griffin MR, Pekka Nuorti J, Grijalva CG. Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States. Clin. Infect. Dis.46(11), 1664–1672 (2008).
   PubMed Web of Science ®Google Scholar
• Park IH, Pritchard DG, Cartee R et al. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J. Clin. Microbiol.45(4), 1225–1233 (2007).
   PubMed Web of Science ®Google Scholar
• Park IH, Park S, Hollingshead SK, Nahm MH. Genetic basis for the new pneumococcal serotype, 6C. Infect. Immun.75(9), 4482–4489 (2007).
   PubMed Web of Science ®Google Scholar
• Vives M, Garcia ME, Saenz P et al. Nasopharyngeal colonization in Costa Rican children during the first year of life. Pediatr. Infect. Dis. J.16(9), 852–858 (1997).
   PubMed Web of Science ®Google Scholar
• Ekdahl K, Ahlinder I, Hansson HB et al. Duration of nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae: experiences from the South Swedish Pneumococcal Intervention Project. Clin. Infect. Dis.25(5), 1113–1117 (1997).
   PubMed Web of Science ®Google Scholar
• Coles CL, Kanungo R, Rahmathullah L et al. Pneumococcal nasopharyngeal colonization in young South Indian infants. Pediatr. Infect. Dis. J.20(3), 289–295 (2001).
   PubMed Web of Science ®Google Scholar
• Hendley JO, Sande MA, Stewart PM, Gwaltney JM Jr. Spread of Streptococcus pneumoniae in families. I. Carriage rates and distribution of types. J. Infect. Dis.132(1), 55–61 (1975).
   PubMed Web of Science ®Google Scholar
• Leino T, Auranen K, Jokinen J et al. Pneumococcal carriage in children during their first two years: important role of family exposure. Pediatr. Infect. Dis. J.20(11), 1022–1027 (2001).
   PubMed Web of Science ®Google Scholar
• Lopez B, Cima MD, Vazquez F et al. Epidemiological study of Streptococcus pneumoniae carriers in healthy primary-school children. Eur. J. Clin. Microbiol. Infect. Dis.18(11), 771–776 (1999).
   PubMed Web of Science ®Google Scholar
• Schuchat A, Hilger T, Zell E et al. Active bacterial core surveillance of the emerging infections program network. Emerg. Infect. Dis.7(1), 92–99 (2001).
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Yothers G, Dagan R et al. Multinational study of pneumococcal serotypes causing acute otitis media in children. Pediatr. Infect. Dis. J.21(11), 1008–1016 (2002).
   PubMed Web of Science ®Google Scholar
• Joloba ML, Windau A, Bajaksouzian S et al. Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media. Clin. Infect. Dis.33(9), 1489–1494 (2001).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction – eight states, 1998–2005. MMWR Morb. Mortal. Wkly Rep.57(6), 144–148 (2008).
   PubMedGoogle Scholar
• Maiden MC, Bygraves JA, Feil E et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc. Natl Acad. Sci. USA95(6), 3140–3145 (1998).
   PubMed Web of Science ®Google Scholar
• Obert CA, Gao G, Sublett J, Tuomanen EI, Orihuela CJ. Assessment of molecular typing methods to determine invasiveness and to differentiate clones of Streptococcus pneumoniae. Infect. Genet. Evol.7(6), 708–716 (2007).
   PubMed Web of Science ®Google Scholar
• Coffey TJ, Enright MC, Daniels M et al. Serotype 19A variants of the Spanish serotype 23F multiresistant clone of Streptococcus pneumoniae. Microb. Drug Resist.4(1), 51–55 (1998).
   PubMed Web of Science ®Google Scholar
• Bartlett J. Treatment of community-acquired pneumonia. Chemotherapy46(Suppl. 1), 24–31 (2000).
   PubMed Web of Science ®Google Scholar
• Bartlett JG, Mundy LM. Community-acquired pneumonia. N. Engl. J. Med.333(24), 1618–1624 (1995).
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis.44(Suppl. 2), S27–S72 (2007).
   PubMed Web of Science ®Google Scholar
• Bradley JS. Management of community-acquired pediatric pneumonia in an era of increasing antibiotic resistance and conjugate vaccines. Pediatr. Infect. Dis. J.21(6), 592–598; discussion 613–594 (2002).
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Good CE, Beall B et al. Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: a quarter century of experience. J. Clin. Microbiol.46(3), 982–990 (2008).
   PubMed Web of Science ®Google Scholar
• Critchley IA, Jacobs MR, Brown SD et al. Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005–2006 and activity of faropenem. Antimicrob. Agents Chemother.52(7), 2639–2643 (2008).
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility testing; Eighteenth Informational Supplement. M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA, USA (2008).
   Google Scholar
• Anon JB, Jacobs MR, Poole MD et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol. Head Neck Surg.130(Suppl. 1), 1–45 (2004).
   PubMed Web of Science ®Google Scholar
• McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA273(3), 214–219 (1995).
   PubMed Web of Science ®Google Scholar
• Fuller JD, Low DE. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin. Infect. Dis.41(1), 118–121 (2005).
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Anon J, Appelbaum PC. Mechanisms of resistance among respiratory tract pathogens. Clin. Lab. Med.24(2), 419–453 (2004).
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics and American Academy of Family Physicians. Diagnosis and management of acute otitis media. Pediatrics113(5), 1451–1465 (2004).
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Dagan R. Antimicrobial resistance among pediatric respiratory tract infections: clinical challenges. Semin. Pediatr. Infect. Dis.15(1), 5–20 (2004).
   PubMedGoogle Scholar
• Dowell SF, Butler JC, Giebink GS et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance – a report from the Drug-Resistant Streptococcuspneumoniae Therapeutic Working Group. Pediatr. Infect. Dis. J.18(1), 1–9 (1999).
   PubMed Web of Science ®Google Scholar
• Benninger MS. Acute bacterial rhinosinusitis and otitis media: changes in pathogenicity following widespread use of pneumococcal conjugate vaccine. Otolaryngol. Head Neck Surg.138(3), 274–278 (2008).
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Poehling KA, Nuorti JP et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics118(3), 865–873 (2006).
   PubMed Web of Science ®Google Scholar
• Zhou F, Shefer A, Kong Y, Nuorti JP. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997–2004. Pediatrics121(2), 253–260 (2008).
   PubMed Web of Science ®Google Scholar
• Sox CM, Finkelstein JA, Yin R, Kleinman K, Lieu TA. Trends in otitis media treatment failure and relapse. Pediatrics121(4), 674–679 (2008).
   PubMed Web of Science ®Google Scholar
• Noel GJ, Blumer JL, Pichichero ME et al. A randomized comparative study of levofloxacin versus amoxicillin/clavulanate for treatment of infants and young children with recurrent or persistent acute otitis media. Pediatr. Infect. Dis. J.27(6), 483–489 (2008).
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA298(15), 1772–1778 (2007).
   PubMed Web of Science ®Google Scholar
• Alpern ER, Alessandrini EA, McGowan KL, Bell LM, Shaw KN. Serotype prevalence of occult pneumococcal bacteremia. Pediatrics108(2), E23 (2001).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.46(No. RR-8), 1–24 (1997).
   PubMedGoogle Scholar
• Baddour LM, Yu VL, Klugman KP et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am. J. Respir. Crit. Care Med.170(4), 440–444 (2004).
   PubMed Web of Science ®Google Scholar
• Tunkel AR, Hartman BJ, Kaplan SL et al. Practice guidelines for the management of bacterial meningitis. Clin. Infect. Dis.39(9), 1267–1284 (2004).
   PubMed Web of Science ®Google Scholar
• Shields B. Prevnar (heptavalent pneumococcal conjugate vaccine): disease prevention in infants and children. J. Pediatr. Health Care15(4), 203–208 (2001).
   PubMedGoogle Scholar
• National, state, and urban area vaccination coverage among children aged 19–35 months – United States, 2004. MMWR Morb. Mortal. Wkly Rep.54(29), 717–721 (2005).
   PubMedGoogle Scholar
• National, state, and urban area vaccination coverage among children aged 19–35 months – United States, 2006. MMWR Morb. Mortal. Wkly Rep.56, 880–885 (2007).
   PubMedGoogle Scholar
• Whitney CG. Impact of conjugate pneumococcal vaccines. Pediatr. Infect. Dis. J.24(8), 729–730 (2005).
   PubMed Web of Science ®Google Scholar
• Pelton SI, Huot H, Finkelstein JA et al. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J.26(6), 468–472 (2007).
   PubMed Web of Science ®Google Scholar
• Messina AF, Katz-Gaynor K, Barton T et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr. Infect. Dis. J.26(6), 461–467 (2007).
   PubMed Web of Science ®Google Scholar
• Moore MR, Gertz RE, Jr., Woodbury RL et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J. Infect. Dis.197(7), 1016–1027 (2008).
   PubMed Web of Science ®Google Scholar
• Darrieux M, Moreno AT, Ferreira DM et al. Recognition of pneumococcal isolates by antisera raised against PspA fragments from different clades. J. Med. Microbiol.57(Pt 3), 273–278 (2008).
   PubMed Web of Science ®Google Scholar
• Widdowson CA, Klugman KP. Molecular mechanisms of resistance to commonly used non-blactam drugs in Streptococcus pneumoniae. Semin. Respir. Infect.14(3), 255–268 (1999).
   PubMedGoogle Scholar
• Smith HJ, Nichol KA, Hoban DJ, Zhanel GG. Stretching the mutant prevention concentration (MPC) beyond its limits. J. Antimicrob. Chemother.51(6), 1323–1325 (2003).
   PubMed Web of Science ®Google Scholar
• Hakenbeck R, Kaminski K, Konig A et al. Penicillin-binding proteins in β-lactam-resistant Streptococcus pneumoniae. Microb. Drug Resist.5(2), 91–99 (1999).
   PubMed Web of Science ®Google Scholar
• Janoir C, Zeller V, Kitzis MD, Moreau NJ, Gutmann L. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob. Agents Chemother.40(12), 2760–2764 (1996).
   PubMed Web of Science ®Google Scholar
• Piddock LJ, Johnson MM, Simjee S, Pumbwe L. Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother.46(3), 808–812 (2002).
   PubMed Web of Science ®Google Scholar
• Sinus and Allergy Healthcare Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Sinus and Allergy Health Partnership. Otolaryngol. Head Neck Surg.123(1 Pt 2), 5–31 (2000).
   PubMed Web of Science ®Google Scholar
• Jacobs MR. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure. Clin. Infect. Dis.35(5), 565–569 (2002).
   PubMed Web of Science ®Google Scholar
• Lonks JR, Garau J, Gomez L et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin. Infect. Dis.35(5), 556–564 (2002).
   PubMed Web of Science ®Google Scholar
• Dagan R, Johnson CE, McLinn S et al. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatr. Infect. Dis. J.19(2), 95–104 (2000).
   PubMed Web of Science ®Google Scholar
• Dagan R, Leibovitz E, Fliss DM et al. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob. Agents Chemother.44(1), 43–50 (2000).
   PubMed Web of Science ®Google Scholar
• Jenkins SG, Brown SD, Farrell DJ. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1–4. Ann. Clin. Microbiol. Antimicrob.7, 1 (2008).
   PubMedGoogle Scholar
• Widdowson CA, Klugman KP. Emergence of the M phenotype of erythromycin-resistant pneumococci in South Africa. Emerg. Infect. Dis.4(2), 277–281 (1998).
   PubMed Web of Science ®Google Scholar
• Hsueh PR, Teng LJ, Lee LN et al. Increased prevalence of erythromycin resistance in streptococci: substantial upsurge in erythromycin-resistant M phenotype in Streptococcus pyogenes (1979–1998) but not in Streptococcus pneumoniae (1985–1999) in Taiwan. Microb. Drug Resist.8(1), 27–33 (2002).
   PubMed Web of Science ®Google Scholar
• Marchandin H, Jean-Pierre H, Jumas-Bilak E et al. Distribution of macrolide resistance genes erm(B) and mef(A) among 160 penicillin-intermediate clinical isolates of Streptococcus pneumoniae isolated in southern France. Pathol. Biol.49(7), 522–527 (2001).
   PubMedGoogle Scholar
• Hoffman HL, Klepser ME, Ernst EJ et al. Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model. Antimicrob. Agents Chemother.47(2), 739–746 (2003).
   PubMed Web of Science ®Google Scholar
• Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev.65(2), 232–260 (2001).
   PubMed Web of Science ®Google Scholar
• Montanari MP, Cochetti I, Mingoia M, Varaldo PE. Phenotypic and molecular characterization of tetracycline- and erythromycin-resistant strains of Streptococcus pneumoniae. Antimicrob. Agents Chemother.47(7), 2236–2241 (2003).
   PubMed Web of Science ®Google Scholar
• Widdowson CA, Klugman KP, Hanslo D. Identification of the tetracycline resistance gene, tet(O), in Streptococcus pneumoniae. Antimicrob. Agents Chemother.40(12), 2891–2893 (1996).
   PubMed Web of Science ®Google Scholar
• Luna VA, Roberts MC. The presence of the tetO gene in a variety of tetracycline-resistant Streptococcus pneumoniae serotypes from Washington state. J. Antimicrob. Chemother.42(5), 613–619 (1998).
   PubMed Web of Science ®Google Scholar
• Taylor DE, Chau A. Tetracycline resistance mediated by ribosomal protection. Antimicrob. Agents Chemother.40(1), 1–5 (1996).
   PubMed Web of Science ®Google Scholar
• Goldstein FW, Kitzis MD, Acar JF. N, N-dimethylglycyl-amido derivative of minocycline and 6-demethyl-6-desoxytetracycline, two new glycylcyclines highly effective against tetracycline-resistant Gram-positive cocci. Antimicrob. Agents Chemother.38(9), 2218–2220 (1994).
   PubMed Web of Science ®Google Scholar
• Dagan R, Leibovitz E, Cheletz G, Leiberman A, Porat N. Antibiotic treatment in acute otitis media promotes superinfection with resistant Streptococcus pneumoniae carried before initiation of treatment. J. Infect. Dis.183(6), 880–886 (2001).
   PubMed Web of Science ®Google Scholar
• McCormick AW, Whitney CG, Farley MM et al. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat. Med.9(4), 424–430 (2003).
   PubMed Web of Science ®Google Scholar
• Lipsitch M. Measuring and interpreting associations between antibiotic use and penicillin resistance in Streptococcus pneumoniae. Clin. Infect. Dis.32(7), 1044–1054 (2001).
   PubMed Web of Science ®Google Scholar
• Dagan R, Leibovitz E. Bacterial eradication in the treatment of otitis media. Lancet Infect. Dis.2(10), 593–604 (2002).
   PubMed Web of Science ®Google Scholar
• Giebink GS. Childhood sinusitis: pathophysiology, diagnosis and treatment. Pediatr. Infect. Dis. J.13(1 Suppl. 1), S55–S58 (1994).
   PubMed Web of Science ®Google Scholar
• Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin. Infect. Dis.15(1), 77–83 (1992).
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Appelbaum PC. Antibiotic-resistant pneumococci. Rev. Med. Microbiol.6, 77–93 (1995).
   Google Scholar
• Doern GV. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am. J. Med.99(6B), S3–S7 (1995).
   Web of Science ®Google Scholar
• Jacobs MR, Bajaksouzian S, Zilles A et al. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance Study. Antimicrob. Agents Chemother.43(8), 1901–1908 (1999).
   PubMed Web of Science ®Google Scholar
• Jacobs MR. Increasing antibiotic resistance among otitis media pathogens and their susceptibility to oral agents based on pharmacodynamic parameters. Pediatr. Infect. Dis. J.19(Suppl. 5), S47–S55; discussion S55–S46 (2000).
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Koornhof HJ, Robins-Browne RM et al. Emergence of multiple resistant pneumococci. N. Engl. J. Med., 299(14), 735–740 (1978).
   PubMed Web of Science ®Google Scholar
• Caputo GM, Appelbaum PC, Liu HH. Infections due to penicillin-resistant pneumococci. Clinical, epidemiologic, and microbiologic features. Arch. Intern. Med.153(11), 1301–1310 (1993).
   PubMedGoogle Scholar
• Appelbaum PC, Bhamjee A, Scragg JN et al.Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet2(8046), 995–997 (1977).
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother.52(2), 229–246 (2003).
   PubMed Web of Science ®Google Scholar
• Fasola EL, Bajaksouzian S, Appelbaum PC, Jacobs MR. Variation in erythromycin and clindamycin susceptibilities of Streptococcus pneumoniae by four test methods. Antimicrob. Agents Chemother.41(1), 129–134 (1997).
   PubMed Web of Science ®Google Scholar
• Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N. Engl. J. Med.341(4), 233–239 (1999).
   PubMed Web of Science ®Google Scholar
• von Gottberg A, Klugman KP, Cohen C et al. Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study. Lancet371(9618), 1108–1113 (2008).
   PubMed Web of Science ®Google Scholar
• Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin. Microbiol. Infect.11(12), 974–984 (2005).
   PubMed Web of Science ®Google Scholar
• Davies TA, Shang W, Bush K, Flamm RK. Activity of doripenem and comparator β-lactams against US clinical isolates of Streptococcus pneumoniae with defined mutations in the penicillin-binding domains of pbp1a, pbp2b and pbp2x. J. Antimicrob. Chemother.61(3), 751–753 (2008).
   PubMed Web of Science ®Google Scholar
• Hebeisen P, Heinze-Krauss I, Angehrn P et al.in vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother.45(3), 825–836 (2001).
   PubMed Web of Science ®Google Scholar
• Jones RN, Huynh HK, Biedenbach DJ, Fritsche TR, Sader HS. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J. Antimicrob. Chemother.54(1), 144–154 (2004).
   PubMed Web of Science ®Google Scholar
• Fritsche TR, Sader HS, Jones RN. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005–2006). Diagn. Microbiol. Infect. Dis.61(1), 86–95 (2008).
   PubMed Web of Science ®Google Scholar
• Tanitame A, Oyamada Y, Ofuji K et al. Synthesis and antibacterial activity of novel and potent DNA gyrase inhibitors with azole ring. Bioorg. Med. Chem.12(21), 5515–5524 (2004).
   PubMed Web of Science ®Google Scholar
• Tanitame A, Oyamada Y, Ofuji K et al. Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives. J. Med. Chem.47(14), 3693–3696 (2004).
   PubMed Web of Science ®Google Scholar
• Inagaki H, Takahashi H, Takemura M. Synthesis and antibacterial activity of novel 6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-4-oxoquinoline-3-carboxylic acids bearing cyclopropane-fused 2-amino-8-azabicyclo[4.3.0]nonan-8-yl substituents at the C-7 position. Bioorg. Med. Chem. Lett.14(20), 5193–5198 (2004).
   PubMed Web of Science ®Google Scholar
• Keating GM, Scott LJ. Moxifloxacin: a review of its use in the management of bacterial infections. Drugs64(20), 2347–2377 (2004).
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Bajaksouzian S, Windau A et al.In vitro activity of the new quinolone WCK 771 against staphylococci. Antimicrob. Agents Chemother.48(9), 3338–3342 (2004).
   PubMed Web of Science ®Google Scholar
• Pankuch GA, Jacobs MR, Khorakiwala H et al. Antipneumococcal activities of WCK 771A and WCK 919 (two new quinolones) compared to 12 other agents against 177 quinolone-susceptible pneumococci. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 16–19 December (2001) (Abstract F-541).
   Google Scholar
• Otani T, Tanaka M, Ito E et al.In vitro and invivo antibacterial activities of DK-507k, a novel fluoroquinolone. Antimicrob. Agents Chemother.47(12), 3750–3759 (2003).
   PubMed Web of Science ®Google Scholar
• Nilius AM, Shen LL, Hensey-Rudloff D et al.In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob. Agents Chemother.47(10), 3260–3269 (2003).
   PubMed Web of Science ®Google Scholar
• Ackermann G, Rodloff AC. Drugs of the 21st Century: telithromycin (HMR 3647) – the first ketolide. J. Antimicrob. Chemother.51(3), 497–511 (2003).
   PubMed Web of Science ®Google Scholar
• Fogarty CM, Kohno S, Buchanan P, Aubier M, Baz M. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin. J. Antimicrob. Chemother.51(4), 947–955 (2003).
   PubMed Web of Science ®Google Scholar
• Park C, Blais J, Lopez S et al. VIC-105555, a new lincosamide with improved in vivo efficacy and good in vitro activity. Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 30 October–2 November (2004) (Abstract F-1392).
   Google Scholar
• Blais J, Park C, Maniar M et al. Bactericidal activity, postantibiotic effect and frequency of resistance of the novel lincosamide VIC-105555. Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 30 October–2 November (2004) (Abstract F-1391).
   Google Scholar
• Tembe V, Chen D, Scott L et al. Improved Pharmacokinetics of VIC-105555: long half-life and large volume of distribution in multiple species. Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 30 October–2 November (2004) (Abstract F-1395).
   Google Scholar
• Ament PW, Jamshed N, Horne JP. Linezolid: its role in the treatment of Gram-positive, drug-resistant bacterial infections. Am. Fam. Physician65(4), 663–670 (2002).
   PubMed Web of Science ®Google Scholar
• Hoellman DB, Lin G, Ednie LM et al. Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents. Antimicrob. Agents Chemother.47(3), 1148–1150 (2003).
   PubMed Web of Science ®Google Scholar
• Manzella JP. Quinupristin–dalfopristin: a new antibiotic for severe Gram-positive infections. Am. Fam. Physician64(11), 1863–1866 (2001).
   PubMed Web of Science ®Google Scholar
• Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin. Infect. Dis.38(7), 994–1000 (2004).
   PubMed Web of Science ®Google Scholar
• Pertel PE, Bernardo P, Fogarty C et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin. Infect. Dis.46(8), 1142–1151 (2008).
   PubMed Web of Science ®Google Scholar
• Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J. Infect. Dis.191(12), 2149–2152 (2005).
   PubMed Web of Science ®Google Scholar
• Murphy S, Pinney RJ. Teicoplanin or vancomycin in the treatment of Gram-positive infections? J. Clin. Pharm. Ther.20(1), 5–11 (1995).
   PubMed Web of Science ®Google Scholar
• Brown GM. The biosynthesis of folic acid. II. Inhibition by sulfonamides. J. Biol. Chem.237, 536–540 (1962).
   PubMed Web of Science ®Google Scholar
• Hitchings GH, Burchall JJ. Inhibition of folate biosynthesis and function as a basis for chemotherapy. Adv. Enzymol. Relat. Areas Mol. Biol.27, 417–468 (1965).
   PubMedGoogle Scholar
• Hartman PG. Molecular aspects and mechanism of action of dihydrofolate reductase inhibitors. J. Chemother.5(6), 369–376 (1993).
   PubMed Web of Science ®Google Scholar
• Schneider P, Hawser S, Islam K. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg. Med. Chem. Lett.13(23), 4217–4221 (2003).
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Good CE, Windau A et al. AR-709, a novel diaminopyrimidine compound: activity against Streptococcus pneumoniae. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy 2006. San Francisco, CA, USA, 27–30 September (2006) (Abstract F1–1956).
   Google Scholar
• Isaacson G, Aronoff SC. Linezolid for tympanostomy tube otorrhea caused by methicillin-resistant Staphylococcus aureus and multiple drug-resistant Streptococcus pneumoniae. Int. J. Pediatr. Otorhinolaryngol.72(5), 647–651 (2008).
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Appelbaum PC. Streptococcus pneumoniae: activity of newer agents against penicillin-resistant strains. Curr. Infect. Dis. Rep.1(1), 13–21 (1999).
   PubMedGoogle Scholar
• Hoellman DB, Lin G, Jacobs MR, Appelbaum PC. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents. J. Antimicrob. Chemother.43(5), 645–649 (1999).
   PubMed Web of Science ®Google Scholar
• Pankuch GA, Hoellman DB, Jacobs MR, Appelbaum PC. Antipneumococcal activity of MEN 10700, a new penem, compared with other compounds, by MIC and time-kill kinetics. J. Antimicrob. Chemother.44(3), 381–384 (1999).
   PubMed Web of Science ®Google Scholar
• Pankuch GA, Visalli MA, Jacobs MR, Appelbaum PC. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob. Agents Chemother.42(3), 624–630 (1998).
   PubMed Web of Science ®Google Scholar
• Pankuch GA, Davies TA, Jacobs MR, Appelbaum PC. Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents. Antimicrob. Agents Chemother.46(1), 42–46 (2002).
   PubMed Web of Science ®Google Scholar
• Jones RN, Mutnick AH, Varnam DJ. Impact of modified nonmeningeal Streptococcus pneumoniae interpretive criteria (NCCLS M100-S12) on the susceptibility patterns of five parenteral cephalosporins: report from the SENTRY antimicrobial surveillance program (1997 to 2001). J. Clin. Microbiol.40(11), 4332–4333 (2002).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Jones RN. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide. Diagn. Microbiol. Infect. Dis.28(4), 157–163 (1997).
   PubMed Web of Science ®Google Scholar
• Jones RN, Ross JE, Fritsche TR, Sader HS. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J. Antimicrob. Chemother.57(2), 279–287 (2006).
   PubMed Web of Science ®Google Scholar
• Critchley IA, Brown SD, Traczewski MM, Tillotson GS, Janjic N. National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005–2006 U.S. faropenem surveillance study. Antimicrob. Agents Chemother.51(12), 4382–4389 (2007).
   PubMed Web of Science ®Google Scholar
• Song JH, Ko KS, Lee MY et al.In vitro activities of ertapenem against drug-resistant Streptococcus pneumoniae and other respiratory pathogens from 12 Asian countries. Diagn. Microbiol. Infect. Dis.56(4), 445–450 (2006).
   PubMed Web of Science ®Google Scholar
• Marchese A, Gualco L, Schito AM, Debbia EA, Schito GC. In vitro activity of ertapenem against selected respiratory pathogens. J. Antimicrob. Chemother.54(5), 944–951 (2004).
   PubMed Web of Science ®Google Scholar